Inter-Institutional Dynamics and Impact of Fluconazole-Resistant Candida parapsilosis

Maya Korem1,2, Shelly Reich3, Galia Rahav4,5

  • 1Department of Clinical Microbiology and Infectious Diseases, Hadassah Medical Center, Jerusalem, Israel.

Mycoses
|January 8, 2025
PubMed
Abstract

Insights

Fluconazole-resistant Candida parapsilosis infections are increasing in Israeli hospitals. While resistance is linked to microbiological failure, clinical outcomes and mortality were not significantly different, highlighting the need for infection control.

Area of Science:

  • Medical Mycology
  • Infectious Diseases
  • Antimicrobial Resistance

Background:

  • Increasing incidence of fluconazole-resistant Candida parapsilosis bloodstream infections in Israeli hospitals.
  • Unclear impact of azole resistance on patient outcomes.

Purpose of the Study:

  • Determine the frequency, resistance mechanisms, molecular epidemiology, and clinical outcomes of azole-resistant C. parapsilosis bloodstream infections.
  • Investigate risk factors associated with fluconazole resistance.

Main Methods:

  • Collected and analyzed 192 C. parapsilosis isolates from four Israeli hospitals (2005-2022).
  • Performed antifungal susceptibility testing, ERG11 gene sequencing, and multilocus microsatellite genotyping.
  • Utilized logistic regression to identify risk factors and compared clinical outcomes between susceptible and resistant isolates.

Main Results:

  • 41% of C. parapsilosis isolates were resistant to fluconazole, often associated with the ERG11 Y132F substitution.
  • Identified increasing age, ICU stay, haemodialysis, and prior antibiotic use as risk factors for resistance.
  • Nosocomial spread of hospital-specific clones was observed, with resistance linked to higher microbiological failure rates but not clinical outcomes or mortality.

Conclusions:

  • High rates of fluconazole resistance in C. parapsilosis are driven by hospital-acquired infections with specific resistant clones.
  • Fluconazole resistance increases the risk of microbiological treatment failure.
  • Effective strategies are required to curb the nosocomial transmission of C. parapsilosis.

Related Concept Videos

Impact of Pharmacokinetic–Pharmacodynamic Models: Regulatory Decisions01:15

Impact of Pharmacokinetic–Pharmacodynamic Models: Regulatory Decisions

PK–PD modeling has significantly influenced FDA regulatory decisions, particularly drug approval, dosage optimization, and labeling. These models integrate pharmacokinetics (PK) and pharmacodynamics (PD) to predict drug behavior and effects, aiding in optimizing dosing regimens and enhancing the probability of clinical trial success.One notable example is Nesiritide (Natrecor®), a recombinant human brain natriuretic peptide for treating acute decompensated congestive heart failure...
85
Fungal Phylum Microsporidia01:28

Fungal Phylum Microsporidia

Microsporidia are a group of obligate intracellular fungi that were initially classified as protists but were later reclassified based on phylogenetic, molecular, and structural evidence linking them to the Chytridiomycota. These unicellular, non-motile organisms are highly specialized parasites that infect a wide range of animal hosts, including humans. They have evolved extensive genomic and metabolic reductions, making them highly dependent on their hosts for survival.Morphology and Genomic...
747
Diversity of Protists II01:27

Diversity of Protists II

Alveolates are a group of organisms recognized by the presence of alveoli, which are cytoplasmic sacs located beneath the cell membrane. While their function remains uncertain, alveoli may help regulate water balance by controlling how much water enters and leaves the cell. In dinoflagellates, these structures may serve as armor plates. There are three major types of alveolates: ciliates, which move using cilia; dinoflagellates, which use flagella for movement; and apicomplexans, which are...
2.2K
Antifungal Agents01:15

Antifungal Agents

Amphotericin B is a broad-spectrum antifungal agent that exploits structural differences between fungal and mammalian cell membranes. Its amphipathic structure—featuring a hydrophobic polyene-lactone ring and a hydrophilic region containing mycosamine and carboxylic acid groups—enables selective binding to ergosterol, a sterol predominantly found in fungal plasma membranes. This selective interaction underlies the drug’s antifungal activity, although weak binding to...
89